Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.
Article Details
- CitationCopy to clipboard
Alshehri FS
Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.
Drug Des Devel Ther. 2023 Mar 21;17:851-861. doi: 10.2147/DDDT.S402362. eCollection 2023.
- PubMed ID
- 36974332 [ View in PubMed]
- Abstract
Tapentadol is an analgesic compound that acts centrally to attenuate pain. Previous studies have shown that tapentadol has dual mechanisms of action as a mu-opioid receptor agonist and noradrenaline re-uptake inhibition. Therefore, tapentadol provides a great advantage over classic opioids in pain management from nociceptive to neuropathic. Cumulative evidence from in vitro data suggests that tapentadol effect of norepinephrine re-uptake could be a new target that overcomes other classic opioids in chronic neuropathic pain. Compared to tramadol and other opioids, tapentadol is associated with fewer adverse effects than tramadol. Tapentadol is a new alternative to treat acute, chronic, and neuropathic pain. Thus, this review article was focused on understanding the studies that led to the development of tapentadol as a novel analgesic drug and its advantages over conventional opioids. Thus, tapentadol is a good alternative with fewer adverse effects and is available for human use.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Tapentadol Delta-type opioid receptor Protein Humans UnknownAgonistDetails Tapentadol Kappa-type opioid receptor Protein Humans UnknownAgonistDetails Tapentadol Mu-type opioid receptor Protein Humans UnknownAgonistDetails Tapentadol Sodium-dependent noradrenaline transporter Protein Humans UnknownInhibitorDetails Tapentadol Sodium-dependent serotonin transporter Protein Humans UnknownInhibitorDetails